Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase

Related Keywords

United States ,Australia ,New York ,American ,Australian ,Jonathan Finn ,Tessa Cigler ,Eric Van Zanten ,Matthew Goetz ,Development Expense ,Atossa Therapeutics Inc ,Weill Cornell Breast Center ,Mayo Clinic Women Cancer Program ,American Association For Cancer Research ,Nasdaq ,Mayo Clinic Comprehensive Cancer Center ,Australian Taxation Office ,Exchange Commission ,Vantage Consulting Group ,Endoxifen Clinical Trial ,Re Evaluating Conditions ,Active Surveillance Suitability ,Ductal Carcinoma In Situ ,Oestrogen Receptor ,Human Epidermal Growth Factor Receptor ,Endoxifen Versus ,American Association ,Cancer Research ,Mayo Clinic Women ,Executive Vice President ,Chief Investment Officer ,Steven Quay ,Chief Executive ,Year Ended December ,Administrative Expense ,Selective Estrogen Receptor Modulator ,Private Securities Litigation Reform Act ,Nasdaq Stock Market ,Annual Reports ,Quarterly Reports ,